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Abstract
A positive test result for BRCA1/2 gene mutation is a substantial risk factor for breast and ovarian cancer. However,
testing is not always covered by insurance, even for high risk women. Variables affecting willingness to pay (WTP) have
implications for clinic-based and direct-to-consumer testing. The relative impact of objective and subjective numeracy on
WTP, in the context of worry, perceived risk (of having the mutation and developing breast cancer) and family history,
was examined in 299 high-risk women, not previously tested for BRCA1/2. Objective and subjective numeracy correlated
positively with one another, yet only subjective numeracy correlated (positively) with WTP. This could not be explained
by educational level or worry. In line with the numeracy result, other objective factors including family history, age, and
Ashkenazi descent were not correlated with WTP. Perceived risk of having a mutation was also correlated with WTP,
though perceived risk of developing breast cancer was not, perhaps because it lacks direct connection with testing. Thus,
subjective confidence in the ability to interpret test results and perceived risk of a positive test result are more important
drivers in paying for BRCA1/2 testing than factors more objective and/or further removed from the testing itself (e.g.,
perceived risk of developing cancer, family history). Findings underscore the need for genetic counselling that makes
probabilistic information accessible and intelligible, so as to build confidence and promote accurate perception of mutation
risk and ultimately better decision-making.
Keywords: genetic testing; breast cancer, BRCA1 and 2, subjective numeracy, willingness to pay.

1 Introduction
With the advent of more accurate and affordable genetic
testing (Myriad, 2007), genetic testing is moving beyond
the purview of the physician, with many genetic tests
available over-the counter via a direct-to-consumer (DTC)
approach that treats the consumer rather than the physician as the end-user (e.g., 23andme.com). In the present
study the focus is on the test for BRCA1 and BRCA2
gene mutations—known risk factors for the development
of breast and ovarian cancer (Squiers et al., 2010). As
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insurance does not always fully or even partially cover
the cost of the test, women contemplating BRCA1/2 genetic testing face the important dilemma of how much they
would be willing to pay (WTP) for this test. WTP may
be influenced by both objective and subjective factors, including actual numeric skill and perceived comfort with
numeric data of the type produced by the test. This decision applies to testing that occurs in conventional, clinicbased settings, as well as in direct-to-consumer testing.
Numeracy, the ability to understand and manipulate
numbers, has been shown to play a role in understanding
medical risk information (Donelle, Arocha, & HoffmanGoetz, 2008; Hanoch, Miron-Shatz, & Himmelstein,
2010; Peters & Levin, 2008; Schwartz, Woloshin, Black,
& Welch, 1997), and to lead to better financial decisions (Wood et al., 2011). Indeed, low numeracy is pervasive and results in more constrained informed patient
choice, reduced medication compliance, limited access to
treatments, impaired risk communication, and ultimately
poorer medical outcomes (Nelson et al., 2008; Nelson,
Moser, & Han, 2013). Objective numeracy scales examine
comprehension of frequency, probability and percentages
(Schwartz et al., 1997; Lipkus, Samsa, & Rimer, 2001).
In contrast, the subjective numeracy scale (SNS) measures
perceived ability to perform various mathematical operations and preference for the use of numeric rather than textual information (Fagerlin et al., 2007). SNS can differen-
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tiate among people with objectively low and high numeracy skills across different demographic groups, but, compared with the objective scale questions, SNS is quicker to
administer and provides a more agreeable experience for
participants (Galesic & Garcia-Retamero, 2010; Fagerlin
et al., 2007). This latter point has practical implications,
as some patients may be reluctant to complete an objective numeracy questionnaire but still agree to complete the
SNS questionnaire.
A crucial element in validating the SNS scale was showing its correlation with objective numeracy (Fagerlin et al.,
2007). Objective and subjective numeracy have also been
shown to correlate positively in a representative sample
of the US population (Nelson, Moser & Han, 2013), as
well as in German and US samples (Galesic & GarciaRetamero, 2009), and in older adults, who make relatively
more decisions about their medical care (Rolison, Wood,
Hanoch & Liu, 2013). However, some evidence suggests
that subjective and objective numeracy do not measure
an identical construct (Liberali et al., 2012). Studies examining the link between numeracy, whether objective or
subjective, and WTP for genetic testing, are sparse. To
bridge this gap in the literature, we examined the relative
impact of objective and subjective numeracy on WTP for
BRCA1/2 testing.
We recruited high-risk women, with a family history of
breast or ovarian cancer, from the registrants of the Cancer Genetics Network (CGN). On top of the family history
for these specific women, breast cancer is the most prevalent cancer among women with a family history of breast
cancer; thus as a group, these women are highly motivated to consider BRCA1/2 testing to alert family members and consider treatment options, including enhanced
surveillance of breast cancer for early detection. However,
understanding the exact risk associated with the BRCA1/2
gene mutation is difficult (Hanoch et al., 2010). The difficulty may reduce WTP to varying degrees, depending
upon objective and/or subjective numeracy. Further, other
objective (e.g., age, family history) and subjective (e.g.,
perceived risk of mutation and/or disease, worry that the
testing may lead to discovery of illness) factors may also
affect WTP.
We expected that objective and subjective numeracy
would be positively correlated. Further, as test results consist primarily of numeric information, we hypothesized
that women with higher numeracy—both subjective and
objective—would be more likely to pay more for the testing, with a greater role for subjective numeracy, given
that it reflects actual perception of facility with numbers
(Fagerlin et al., 2007). As older age is a risk factor for
breast cancer (National Cancer Institute, 2013), we also
hypothesized that older women would be more likely to
pay more for testing. Likewise, we hypothesized that the
more risk-related family history a woman has (Ashkenazi

origin; having a relative who tested positive for BRCA 1/2;
and number of relatives with breast or ovarian cancer) the
higher her WTP for BRCA1/2 testing. In addition, we expected a higher WTP in women who are more worried that
the test might detect illness as well as those with higher
perceived risk of mutation and developing the disease.

2 Method
2.1

Participants

Eligible participants were female registrants in the Cancer Genetics Network (CGN), a US national populationbased cancer registry. Inclusion criteria were being unaffected by breast or ovarian cancer, not previously tested
for the BRCA1/2 mutation, and with at least one relative
diagnosed with breast cancer at age 45 or younger, two
or more relatives diagnosed with breast cancer at age 50
or younger, at least one relative diagnosed with ovarian
cancer, or at least one relative diagnosed with male breast
cancer. Consent was obtained and the survey completed
via emails from the local CGN branch. The CGN is a
U.S. network of centers that serves as a resource for investigators conducting research on the genetic basis of human cancer susceptibility, integration of this information
into medical practice, and behavioral, ethical, and public
health issues associated with human genetics. A core data
set is available on each registrant and contains information
on socio-demographic characteristics (though not income
information).
Our participants were recruited and registered in the
CGN database by local hospital clinics. They initially provided CGN with baseline data including demographics,
family history, and disease history. After obtaining approval from the centers’ Institutional Review Boards and
consent from all study participants, we extracted a deidentified data set containing the relevant data from the
CGN database for analysis. The Appendix shows their
characteristics.

2.2

Procedure

Respondents completed an online survey. They were assured that no knowledge of genetics was required to participate and that their identifying information would remain
confidential. Respondents were told that the survey would
take about 30 minutes. They had an option of receiving a
$30 gift card and could skip any question that made them
uncomfortable. Willingness to pay (WTP) for BRCA1/2
mutation testing was the primary variable of interest. Correlates examined were number of relatives with breast or
ovarian cancer, presence of family member(s) testing positive, of Ashkenazi (Eastern European Jewish) descent,
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perceived risk of having a mutation, perceived risk of developing breast cancer, worry that the test might find illness, objective numeracy, subjective numeracy, and age.
Variables were computed as follows:
Willingness to Pay (WTP) for BRCA Genetic Testing:
Responses to the survey question: “How much money
would you be willing to spend on getting tested for the
BRCA1 and BRCA2 gene mutations? $______.” Participants were instructed to assume that testing was not covered by their medical insurance.
Number of Relatives with Breast or Ovarian Cancer:
Number of relatives with breast or ovarian cancer from the
CGN database.
Family Member(s) with Positive Test Result: The concatenated responses to questions from the CGN database,
asking “Has anyone in your family ever tested positive for
a BRCA1 mutation?” and likewise for BRCA2. Response
options were “No”, “Yes”, “Not Sure”, and “Rather Not
Answer” (not selected by any participants). We recorded
the responses as “Yes” (coded ‘3’) if the response to either
question was “Yes”, “No” (coded ‘1’) if the response to
both questions was “No”, and “Unknown” (coded ‘2’) for
all other cases.
Of Ashkenazi (Eastern European Jewish) Descent:
Response options for this CGN database variable were
“Yes”, “No”, or “Unknown”. “No” and “Unknown” were
combined for analysis purposes. Values of this variable
were “No or Unknown” (coded ‘0’) or “Yes” (coded ‘1’).
Perceived Risk of Having the BRCA1/2 Mutation: Responses to the survey question: “What do you think the
chances are that you have the BRCA1 or BRCA2 gene mutation?” Participants responded by placing an “X” on a
number line running from 0 to 100%.
Perceived Risk of Developing Breast Cancer: Responses to the survey question: “What do you think is
the chance of you developing breast cancer?” Again, participants responded by placing an “X” on a number line
running from 0% to 100%.
Worried that Test Might Lead to Discovery of Illness:
Responses to this survey question were on a 5-point scale
with options of “Not Worried At All” (’1’), “Slightly Worried” (‘2’), “Of Medium Worry” (‘3’), “Worried” (‘4’),
and “Very Worried” (‘5’).
Objective Numeracy: Respondents completed three
survey questions to test facility with numbers (e.g., how
many of 1,000 coin flips would come up heads) (Schwartz
et al., 1997). Each question was scored as correct (‘1’) or
incorrect (‘0’). Total number correct was analysed.
Subjective Numeracy: As part of the survey, participants completed the SNS (Fagerlin et al., 2007). The
overall SNS score analysed was the average rating across
all eight SNS questions, with one of the questions reverse
coded.
Age: Participant age (in years) from the CGN database.

3 Results

154

Of 961 eligible participants invited to complete the online
survey, 459 consented and completed the survey, yielding
a response rate of 48%. Of these (based on information
from both the CGN database and the survey), 315 participants had not previously been tested for the BRCA1/2
mutation, and of these, 299 (mean age = 50.08 years, sd
= 7.73; 72% college graduates; 78% married/cohabiting)
responded to the survey question regarding WTP. The
present study focuses on these 299, who were not previously tested. Of these participants, the distribution of
WTP responses was positively skewed, 69% of participants offering to pay ≤$100 (22% of all participants offered $0), 29% offering to pay >$100 to $500, and the
remaining 2% offering to pay $1000 or more. Mean WTP
was $143.66 (sd = 191.57). For total objective numeracy
(possible scores: 0 to 3), the range was 0–3, with a mean
of 2.01 and a standard deviation of 0.93. For the SNS
(possible scores: 1 to 6), the range was 2–6, with a mean
of 4.72 and a standard deviation of 0.83.
WTP was significantly correlated with subjective numeracy (r = .150, P = .009) but not with objective numeracy (r = −.057, P = .326), and these two correlations
were significantly different from one another (Steiger’s
[1980] Z = 3.05, P = .002) despite the substantial correlation between objective numeracy and subjective numeracy
(r =.361, P < .001).
Educational level (less than college graduate vs. college
graduate or graduate school) could not explain the differential correlation between type of numeracy and WTP, as
educational level was correlated with both subjective (r
=.182, P = .002) and objective (r =.185, P = .001) numeracy, and not with WTP (r = −.011, P = .853).
Similarly, worry that the test might find illness could not
explain the differential correlation between type of numeracy and WTP, as worry was (negatively) correlated with
both subjective (r = −.154, P = .008) and objective (r =
−.138, P = .017) numeracy, and not with WTP (r = .066,
P = .252).
WTP was also significantly correlated with perceived
risk of having a mutation (r = .162, P = .007), but not with
perceived risk of developing breast cancer (r = .043, P =
.478), though these two correlations were not significantly
different from one another (Steiger’s Z = 1.71, P = .087).
None of the other variables was correlated with WTP:
number of relatives with breast or ovarian cancer (r = .080,
P = .215), Ashkenazi descent (r = .034, P = .556), or age
(r = −.039, P = .497). Similarly, presence of family member(s) testing positive did not predict WTP (r = −.011, P =
.845), though only four of our participants reported having
such a relative (see Appendix).

155

Judgment and Decision Making, Vol. 9, No. 2, March 2014

Numeracy and willingness to pay for BRCA1/2 testing

4 Discussion

our open-ended method of eliciting WTP, which involved
recording a monetary amount but no financial obligation, is indicative of actual behaviour. Researchers have
used various methods for WTP elicitation, including the
double-bounded, dichotomous-choice approach. See, for
example, a study of SNP-based testing by Neumann and
colleagues (2012), who included $0 responses, as in the
present study. We chose an open-ended methodology to
avoid biasing women by providing a particular number as
a benchmark for the cost of the test. Despite the different
elicitation methods, the median (given the positive skew;
skewness = 2.89, SE = .14) WTP of $100 for our participants is lower than that of Neumann et al. (2012), where
average WTP ranged from $181 to $232. However, their
study included women who tested for the BRCA 1/2 mutation, albeit only women who tested negative. That women
who tested had WTP similar to what they had actually paid
is in line with previous findings (Baron & Maxwell, 1996).
Interestingly, consumers’ WTP for genetic testing, as captured by actual behaviour, appears to be even higher for
some. Early adopters of DTC genome testing, who, compared to the U.S. general population, had high levels of
education and household income, paid $429 to $2000 for
a scan of their genetic profile and propensity to develop
various diseases (Kaufman, Bollinger, Dvoskin, & Scott,
2012). These sums far exceed the WTP range of Neumann
et al. (2012) using hypothetical scenarios, and what our
participants indicated they would pay. However, the price
of genetic testing continues to decline (e.g., as of this writing, 23andMe, Inc. is selling its health test for $99 plus a
monthly information fee), and will likely continue to drop
following the recent US Supreme Court ruling to disallow
patenting of the BRCA gene (Liptak, 2013), which may
lead to the availability of BRCA testing via DTC marketing. Thus, testing is becoming accessible to even more
customers (Wolinsky, 2007), including in settings where
a counsellor is not necessarily present. Indeed, a recent
policy statement asserts that providers and consumers will
need to think in new ways about education, counselling
and informed consent in the setting of DTC genetic testing (Robson et al., 2010).

In view of expected growth in the prevalence of genetic
testing and patient autonomy in making testing decisions,
coupled with the deleterious effect of low numeracy on
medical outcomes (Nelson et al., 2008; Nelson et al.,
2013), this study examined the impact of numeracy upon
willingness to pay for BRCA1/2 testing in women reporting a family history of breast and ovarian cancer. The findings indicate that women with higher subjective numeracy
reported a higher WTP for genetic testing, but the same
result was not obtained for women with higher objective
numeracy or other objective risk factors, including age and
family history. Further, this pattern of results could not
be explained by educational level or worry. Results also
showed a higher WTP for women who perceived a greater
risk of having the mutation. Taken together, these results
support the claim that subjective or emotional factors directly related to the testing are the most important determinants of perceived value (as measured by WTP).
Our finding that WTP is related to subjective but not
objective numeracy is consistent with research suggesting that risk assessment is not performed solely through
cognitive lenses, or “risk as analysis”, but is also based
on instinctive and intuitive reactions, or “risk as feeling”
(Lowenstein, Weber, Hsee, & Welch, 2001). Indeed, research in a variety of contexts has shown that personal experience has led people to perceive hazards as more frequent, themselves as potential future victims, and to think
about risk more often and with greater clarity (Weinstein,
1989). Notably, cancer worry was not related to WTP,
likely because most of our participants (59%) reported no
cancer worry, consistent with the distribution of cancer
worry in both general and high-risk populations, but precluding empirical and theoretical conclusions (Hay, Buckley, & Ostroff, 2004).
That subjective but not objective numeracy correlated
with WTP for testing suggests that comfort level with
probabilistic information is more relevant to WTP for such
information than actual mathematical ability. The obtained divergence in how WTP relates to subjective and
objective numeracy is consistent with recent work by Liberali and colleagues (2012) showing that, although correlated, subjective and objective numeracy measure different constructs. This dovetails with the finding that although 70% of individuals considered themselves “good
with numbers”, only 2% answered all three Schwartz et
al. (1997) objective numeracy questions correctly (Nelson
et al., 2008; see also Nelson et al., 2013). Further, that
numeracy was not a mere proxy for educational level is
consistent with the finding that low numeracy cannot be
reliably inferred on the basis of education, intelligence or
other observable characteristics (Nelson et al., 2008).
One question that may arise is the degree to which

The present results have practical implications for both
conventional clinic-based testing and DTC genetic testing. Although most women continue to test in clinics,
the growing accessibility of DTC is particularly disturbing in light of our finding of the centrality of emotional
relevance in WTP for testing. DTC marketing campaigns
may increase anxiety by exploiting consumers’ emotional
concerns (Gollust, Hull, & Wilfond, 2002). Further,
upon receipt of DTC testing results, consumers of BRCA
test results may experience anxiety and distress (Dohany, Gustafson, Ducaine, & Zakalik, 2012), possibly attributable to inadequate counselling (Brierley et al., 2010).
Our results highlight the importance of combining pre-
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and post-test genetic counselling, standard for adult-onset,
single gene disorder testing (Wade & Wilfond, 2006) with
DTC testing to alleviate distress and guide the consumer
regarding a reasonable cost/benefit analysis prior to testing and realistic implications of the result following testing. Indeed the availability of counselling in clinics may
explain why women with a personal or family history report more negative beliefs about DTC and higher preferences for clinic-based testing (Gray, Hornik, Schwartz, &
Armstrong, 2012). Given our findings, if the counsellor
is aware that emotional relevance may distort the patient’s
decision, he/she will be better able to offer better, more cogent advice. Counsellors should be cognizant of the fact
that women with low subjective numeracy perceive poorer
quality of provider communication and are likely to require more explanation to engage in prevention behaviors
(Ciampa, Osborn, Peterson, & Rothman, 2010; Nelson et
al., 2008). The association between low subjective numeracy and lower WTP for BRCA1/2 testing may be offset by
promoting perception of high quality communication, as
has been shown in the context of screening for colorectal cancer (Ciampa et al., 2010). Specifically, counsellors
should use non-numerical presentation formats, such as
graphical displays and analogies to communicate important statistical information to women with low subjective
numeracy (Galesic & Garcia-Retamero, 2010).
This study has a number of limitations. For example,
our study was cross-sectional, and a number of other variables may have affected our results (e.g., insurance status
and coverage). That our sample was composed of highrisk, mainly white women may limit the generalizability
of our results. Follow-up studies in larger, more heterogeneous samples are needed to confirm our findings and
identify clear predictors of WTP. The risk-level limitation
is mitigated by the fact that BRCA 1/2 genetic testing is
sought mainly by women who are at high risk for developing cancer or have already been diagnosed with cancer
(Ropka et al., 2006). In this regard, rather than a limitation, the sample risk level may be viewed as a strength,
in that our findings are highly relevant to the women most
likely to undergo BRCA 1/2 genetic testing.
The current findings suggest that among women with
a family history of breast or ovarian cancer, women who
perceive themselves as being more numerate and/or at
higher risk of having the BRCA1/2 mutation are willing
to pay more for the testing, but objective numeracy and
other more objective or distant factors (e.g., family history) do not impact WTP judgements. These findings suggest that WTP is primarily an emotional decision and add
to the longstanding concern over offering genetic testing
as a DTC free market commodity (Hudson, Javitt, Burke,
& Byers, 2007), where, presumably, consumers can decide whether or not to make a purchase, and how much to
pay for it.

In terms of measuring patient comprehension, the findings suggest that, when the objective numeracy scale is
perceived as cumbersome, it can be replaced by the SNS.
That subjective numeracy, and not objective numeracy or
objective risk factors determine WTP for breast cancer
testing, highlights the importance of the SNS in clinical
settings.
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Appendix: Demographic and clinical characteristics (N = 299).
n
Cancer center, %

Colorado
Duke
Emory
Johns Hopkins
MD Anderson
Univ. of North Carolina
Univ. of Utah

37% 110
7% 22
4% 12
12% 36
4% 11
4% 13
32% 95

Age, mean years (sd)

50.08 (7.73)

Highest degree or year of school completed, %

≤8 years
High School/GED
Some College/Technical
College+

1%
2
5% 15
23% 69
71% 213

Marital status, %

Single
Married or Living Together
Separated
Divorced
Widowed

9% 26
78% 233
2%
5
10% 30
2%
5

Race, %

American Indian or Alaskan Native 1%
3
Asian
1%
3
Black or African American
1%
4
White
95% 283
More than one race
1%
4
Other
<1%
1

Amount willing to pay (WTP) for BRCA 1/2 testing, mean $ (sd)

$143.66 (191.57)

299

Objective numeracy (Schwartz et al., 1997) (range: 0–3), mean (sd)

2.01 (0.93 )

296

Subjective numeracy (Fagerlin et al., 2007) (overall SNS score), mean (sd) 4.72 (0.83)

299

299

Of Ashkenazi (Eastern European Jewish) descent, %

4%

11

Any family member(s) tested positive for BRCA1 or BRCA2 mutation, %

No
Yes
Unknown

24% 72
1%
4
75% 223

Number of relatives with breast or ovarian cancer, %

1
2
3
4
5
6
7
>7

31%
29%
20%
9%
5%
4%
2%
1%

Perceived risk of mutation, mean % (sd)

32.40% (24.47)

273

Perceived risk of developing breast cancer, mean % (sd)

44.54% (28.73)

274

Worried that test might find illness, %

Not Worried at All
Slightly Worried
Of Medium Worry
Worried
Very Worried

76
71
50
21
11
9
5
2

59% 178
18% 54
12% 36
6% 18
4% 12

All available data shown; amount of missing data varied across the variables. Percentages are out of the total number of
participants with data.
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